QUANTRO Therapeutics Extends Boehringer Ingelheim Partnership for Transcription Factor Cancer Drug Discovery
Key Insights
QUANTRO Therapeutics (search) has extended its strategic collaboration with Boehringer Ingelheim for two additional years to develop first-in-class drug candidates targeting cancer-associated transcription factors.
The partnership follows successful completion of a major high-throughput screening campaign that evaluated over 350,000 compounds and identified functionally validated hits against previously undruggable transcription factors.
QUANTRO is eligible to receive success-based milestone payments up to an estimated total value of around €500 million under the extended agreement.
QUANTRO Therapeutics (search) announced the extension of its strategic collaboration with Boehringer Ingelheim for two additional years, building on progress made since their initial agreement in 2022. The partnership focuses on developing first-in-class drug candidates targeting cancer-associated transcription factors, addressing what the companies describe as high unmet medical needs in cancer treatment.
The extension follows the successful completion of QUANTRO's largest transcriptomic dual-target screening campaign to date, which evaluated over 350,000 compounds to identify candidates specifically targeting selected transcription factors. This achievement represents a significant milestone in targeting what have traditionally been considered "undruggable" proteins.
Breakthrough in Transcription Factor Targeting
Transcription factors serve as central regulators of gene expression and play key roles in cancer development and progression. Despite their clinical relevance, these proteins have remained largely inaccessible to drug development due to technical limitations of conventional assay techniques, which cannot adequately identify direct transcriptional responses caused by drug treatments at early time-points within one hour after dosing.
QUANTRO's proprietary time-resolved transcriptomics platform addresses these limitations by enabling precise characterization of transcriptional responses over time, thereby revealing actionable disease-driving mechanisms. The technology represents a significant advancement over traditional RT-qPCR based technologies like DRUG-seq, which are limited to measuring RNA abundance without capturing information on transcriptional activity and dynamics.
"The identification of functionally validated hits for difficult to drug transcription factor targets, using our HTS screening platform, confirms the precision, impact and maturity of our innovative time-resolved transcriptomics platform," said Dr. Michael Bauer, CEO of QUANTRO. "We look forward to further pushing the boundaries of what is possible in transcriptomic drug discovery."
Significant Financial Commitment
Under the extended agreement, QUANTRO is eligible to receive success-based R&D, regulatory and commercial milestone payments up to an estimated total value of around €500 million. The company has already received initial payments, though specific collaboration terms remain undisclosed. QUANTRO retains full ownership of its technology platform and internal drug discovery programs targeting additional transcription factors beyond the scope of the collaboration.
Technical Achievements and Platform Validation
QUANTRO has achieved several key technical milestones, including technical proof-of-concept, cross-validation of its high-throughput screening technology, and identification of functionally validated hits against previously undruggable transcription factors. The company's platform uniquely quantifies changes in gene expression over time with unprecedented precision and sensitivity.
The Vienna-based company, founded in 2019 as a spin-out from research institutes IMBA (search) and IMP (search), has been supported by Boehringer Ingelheim Venture Fund and Evotec as seed investors since 2020. The ongoing collaboration with Boehringer Ingelheim Oncology provides additional undisclosed proceeds.
Addressing Cancer Treatment Challenges
Cancer remains one of the leading causes of death worldwide, with many patients facing limited treatment options and poor outcomes despite recent therapeutic advances. The partnership aims to address these challenges by developing innovative therapeutics targeting underlying cancer mechanisms previously considered undruggable.
The collaboration will continue to apply QUANTRO's time-resolved transcriptomics platform to advance the discovery of first-in-class small molecule inhibitors of selected oncogenic transcription factors, potentially opening new therapeutic avenues for cancer patients with limited treatment options.